{
    "nct_id": "NCT04650321",
    "official_title": "Evaluating the Feasibility of Pandemic Forward, Telehealth Based Home Based Infusions",
    "inclusion_criteria": "* Current active patient of Rocky Mountain MS Center at the time of final study consent.\n* Between 18-55 years of age at the time of final study consent.\n* Diagnosis of primary progressive or relapsing MS as defined by the 2017 McDonald criteria.19\n* Has at minimum completed their first 600 mg dose of ocrelizumab.\n* Is physically residing in the Denver metro, Fort Collins or Colorado Springs area at the time of final study consent.\n* Has a Patient Determined Disease Steps (PDDS) between 0 to 6.5 20\n* Can complete patient reported outcomes developed and validated as English written scales.\n* Must be able and willing to give meaningful, informed consent via electronic signature prior to participation in the study, in accordance with local and FDA regulatory requirements.\n* Whose treating neurologist at the RMMSC feels that continuing ocrelizumab s medically appropriate based on at the time of final study consent.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 55 Years",
    "exclusion_criteria": "* Not pregnant, intentions to get pregnant or lactating at the time of final study consent and on the day of infusion.\n* Has previously not participated in the SaROD trial at the RMMSC site.\n* Any of the following abnormal laboratory results as processed by a University of Colorado Hospital laboratory site and deemed clinically inappropriate to proceed with a home infusion by the treating neurologist at RMMSC.",
    "miscellaneous_criteria": ""
}